Study of Del-brax (AOC 1020) for People with FSHD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests an experimental medicine called Del-brax (AOC 1020) for people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to see if it can help improve muscle strength and slow the disease. You may be able to join if you have a confirmed FSHD diagnosis and can walk at least 10 meters on your own.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of FSHD type 1 or 2
- You must be able to walk at least 10 meters without help (braces are okay)
- You must not be pregnant, breastfeeding, or planning to get pregnant during the trial
- You must not have taken any other experimental drug in the past month
- You must not have taken certain gene-targeting drugs (oligonucleotides) in the past 9 months
- Your blood pressure needs to be 140/90 or lower at the start of the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
This study looks at how walking changes over time in people with facioscapulohumeral muscular dystrophy (FSHD). It aims to understand walking patterns to help improve future care.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
This study looks at muscle MRI images and walking patterns (3D gait analysis) in people with FSHD. It helps researchers understand how the disease affects movement and muscle over time.
This is a study that follows people who have a confirmed FSHD1 genetic change (and some healthy people for comparison). It may help researchers better understand the condition and how it affects people over time.
Hear when a new Facioscapulohumeral Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.